UAS Drone Corp. — Form 10-Q Summary
Reporting period: Quarter and nine months ended September 30, 2021; unaudited. The supplied filing identifies the registrant as UAS Drone Corp. (with Duke Robotics, Inc. as a subsidiary), although the request metadata names Duke Robotics Corp. Dollar amounts below are in thousands unless otherwise stated.
Business context
The company develops TIKAD, a robotic stabilization system mounted on an unmanned aircraft for remote, precision use of small arms and light weapons. It has generated limited revenue and has not begun meaningful commercialization. In January 2021, its subsidiary entered a collaboration agreement with Elbit Systems Land for global marketing, sales, production, and further development of TIKAD.
Financial performance and position
| Metric | Three months ended September 30, 2021 | Nine months ended September 30, 2021 | Prior comparable period |
|---|---|---|---|
| Revenue | $0 | $500 | $0 for both 2020 periods |
| Gross profit | $0 | $500 | $0 |
| General and administrative expenses | $485 | $918 | $172 and $1,114, respectively |
| Net loss | $787 | $954 | $227 and $1,229, respectively |
| Basic and diluted loss per share | $0.01 | $0.02 | $0.01 and $0.03, respectively |
| Cash used in operating activities | Not separately provided | $64 | $692 used for nine months |
Nine-month gross margin was 100% as reported because the company recorded no cost of sales; revenue included an upfront Elbit fee for engineering materials and transfer support. The filing does not provide a clear quarter-specific revenue contribution beyond reporting no third-quarter revenue.
- Balance sheet at September 30: Cash $3,730; current assets $3,781; total assets $3,791; current liabilities $523; total liabilities $817; stockholders’ equity $2,974. At December 31, 2020, cash was $105 and total liabilities exceeded assets by $1,849.
- Debt and liquidity: Convertible loans and debentures were fully repaid or converted by September 30. Stockholders’ loans of $294 remained, including $274 owed to related parties. No long-term bank loan remained.
- Cash flows: Financing activities provided $3,689 for the nine months, primarily reflecting $4,649 net proceeds from the May share offering, offset in part by $954 in convertible-loan repayments. Cash increased by $3,625 to $3,730.
- Capitalization: Shares outstanding rose to 54,018,813 from 40,075,151 at year-end 2020. The May offering sold 12.5 million shares at $0.40 each and included warrants to buy an additional 12.5 million shares at $0.40, exercisable for 18 months.
Changes, outlook, and risks
- Nine-month revenue of $500 was new and arose mainly from the Elbit collaboration; the company had no revenue in the prior-year period. Nine-month net loss narrowed from $1,229 to $954, while third-quarter net loss increased from $227 to $787.
- Management attributed the nine-month G&A decrease to lower stock-based compensation and legal expenses. It reported no research and development expense in either comparative period.
- Management expected available cash to fund operations through the end of 2023. It also warned that a need for additional capital could require reduced development, further shareholder dilution, or changes to the business strategy, and that inadequate funding could threaten continued operations.
- The Elbit agreement provides for royalties to Duke based on sales, with rates varying by selling-price tiers; Elbit may invest in development and production subject to milestones and can recoup half of qualifying investment, up to $6,000, from half of royalties. The agreement includes termination conditions tied to matters such as cancellation of the customer project.
- The company described itself as an early-stage business and cautioned that forward-looking expectations are uncertain. It said COVID-19 had not materially affected results or liquidity to date, while noting the eventual impact remained uncertain.
- Legal matters disclosed in the filing were settled during 2021: a shareholder-related dispute through transfer of founders’ shares, and a former-vendor dispute for approximately $50.
- The filing reports a $327 fair-value liability related to warrants/options issued in connection with the financing. The nine-month financing expense was $619, including fair-value and convertible-loan-related charges.
Filing inconsistency to note: The financial statements report third-quarter financing expense, net, of $253, while MD&A describes $253 of financial income and gives a rationale that does not clearly reconcile with the statement. The statements also report third-quarter “other income” of $(49). The filing text does not provide a clear explanation reconciling these presentations.
Important facts for investors to verify
- Confirm the character and sustainability of the $500 nine-month Elbit-related revenue, including whether further revenue depends on customer evaluation, production milestones, or commercial sales.
- Review the Elbit agreement’s royalty tiers, investment and recoupment terms, termination rights, and the status of the Asia-Pacific customer project.
- Reconcile the third-quarter financing income/expense disclosures and understand the valuation assumptions behind the $327 warrant-related liability.
- Assess whether the stated cash runway through 2023 remains realistic given operating costs, development plans, and potential funding needs.
- Evaluate dilution exposure from the warrants, outstanding options, and any future capital raising; verify the terms and potential exercise of the 12.5 million warrants.
- Confirm the remaining stockholders’ loan repayment terms and monitor commercialization progress, since the company reported no third-quarter revenue and no R&D expense.